newsfilter
← Latest News
Business Wire·

Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Achieved $47.2 million in RYTELO® net product revenue in Q3 2025 Completed enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis Strengthened leadership team